Navigation Links
Studies Show Combination Laser Therapy Effective At Clearing Acne, Reducing Oil Production
Date:3/5/2009

Dermatologist evaluates the latest laser and light sources approved for treating acne

SAN FRANCISCO, March 5 /PRNewswire-USNewswire/ -- From the removal of childhood birthmarks to skin rejuvenation, laser technology has become a mainstay in dermatology. Now, dermatologists are fine-tuning this technology to safely and effectively treat one of the most common skin conditions that plagues teenagers and adults alike: acne.

Speaking today at the 67th Annual Meeting of the American Academy of Dermatology (Academy), dermatologist Macrene Alexiades-Armenakas, MD, PhD, FAAD, assistant clinical professor of dermatology at Yale University School of Medicine in New Haven, Conn., presented scientific data illustrating how photodynamic therapy combined with a long-pulse, pulsed-dye laser and topical 5-aminolevulinic acid provides long-lasting clearance of acne lesions.

"Laser technology has made great inroads in the treatment of acne, which until recently has been treated almost exclusively - and with varying degrees of success - with topical, systemic and hormonal medications," said Dr. Alexiades-Armenakas. "Now, we have solid evidence-based medicine supporting the effectiveness of certain laser therapies as a long-term solution for treating active acne. The key is to distinguish the benefits and limitations of these available technologies and select the most effective treatments for each acne patient."

Photodynamic Therapy with a Photosensitizer

In a preliminary study, Dr. Alexiades-Armenakas examined whether a combination of photodynamic therapy (PDT) with a photosensitizer known as

topical 5-aminolevulinic acid (ALA) and activated by long-pulse, pulsed dye laser could safely and effectively clear mild to severe cases of acne. PDT works by using laser or light energy - in this case a pulsed dye laser was used - to activate the ALA, which is a solution
'/>"/>

SOURCE American Academy of Dermatology
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Carrington Subsidiary DelSite Initiates Critical Toxicology Studies of Its Nasal Powder Bird Flu Vaccine
2. Advanced Life Sciences to Present Data on Selected Cethromycin Therapeutic Studies at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
3. Sucampo Pharmaceuticals, Inc. Begins Pivotal Phase III Studies of Oral Lubiprostone to Treat Opioid-Induced Bowel Dysfunction (OBD)
4. Schering-Plough Initiates Phase III Studies with Vicriviroc in Treatment- Experienced HIV Patients
5. Phase 2 Clinical Studies Initiated for a Novel Therapeutic Candidate Identified Through Pharmacopeia Collaboration
6. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
7. Studies Suggest Key Correlation Between Lung Cancer Subtype and Treatment Outcomes
8. Isis Announces $1.2 Million Award to Its Ibis Subsidiary to Expand Influenza Detection Capabilities and Enable Large-Scale Influenza Transmission Studies
9. Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
10. Studies Show Body Mass Index Has No Effect on Resolution and Healing of GERD Symptoms
11. Amicus Therapeutics Announces Positive Results From Two Phase 1 Clinical Studies of AT2220 for Pompe Disease

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2009)... N.J., Nov. 20 BD (Becto...ounced the completion of its acquisition of HandyL...t develops and manufactures molecular diagnostic a... BD and HandyLab announced an exclusive agreement ...ys on the HandyLab Jaguar(TM) platform, the first ...
(Date:11/19/2009)...ov. 19 In response to an ever-incr...illegal medicines, Operation Pangea II, involving ...World Health Organization,s International Medical ... highlight the dangers of buying medicines online.... a series of arrests and the seizure of thousands ...
(Date:11/19/2009)...ll., Nov. 19 The D e ...e of its Most Admired Corporate Dealmakers for the...tt as its Most Admired Dealmaker in pharma/biotech...ons and divestitures since January 2006. ,, Ove...s portfolio with a focus on high-growth, innovatio...
Breaking Medicine Technology:BD Completes Acquisition of HandyLab, Inc. 2BD Completes Acquisition of HandyLab, Inc. 3International Operation Combats Online Supply of Counterfeit and Illegal Medicines 2The Deal Names Abbott Top Dealmaker for Second Consecutive Year 2The Deal Names Abbott Top Dealmaker for Second Consecutive Year 3Masimo Radical 7 28R 29 and Rad 57 28R 29 Pulse CO Oximeters 28TM 29 Awarded Airworthiness Release Certification by the United States Army 13839 1Masimo Radical 7 28R 29 and Rad 57 28R 29 Pulse CO Oximeters 28TM 29 Awarded Airworthiness Release Certification by the United States Army 13839 2Masimo Radical 7 28R 29 and Rad 57 28R 29 Pulse CO Oximeters 28TM 29 Awarded Airworthiness Release Certification by the United States Army 13839 3Masimo Radical 7 28R 29 and Rad 57 28R 29 Pulse CO Oximeters 28TM 29 Awarded Airworthiness Release Certification by the United States Army 13839 4Scientists Turn Off Obesity Switch in Mice 56171 1Scientists Turn Off Obesity Switch in Mice 56171 2MassMutual Retirement Services Adds to Taft Hartley Sales Team 56167 1MassMutual Retirement Services Adds to Taft Hartley Sales Team 56167 2MassMutual Retirement Services Adds to Taft Hartley Sales Team 56167 3
...armaceuticals,Inc., today announced a strategic pa...op therapies targeting CD103 for the treatment of ...respiratory, gastrointestinal,and autoimmune indic...that,has been implicated in the activation, homing...atory diseases affecting mucosal regions of the,in...
...ance Therapy Advances on Schedule Follo... EpiCept Corporation,(Nasdaq and OMX Nordic Excha...ts European Union centralized marketing authorizat...ene(TM) is advancing according to the,anticipated .... Ceplene,(histamine dihydrochloride) has demonstr...
Other Medicine Technology:EpiCept Reports Regulatory Progress on Ceplene(TM) 2EpiCept Reports Regulatory Progress on Ceplene(TM) 3EpiCept Reports Regulatory Progress on Ceplene(TM) 4EpiCept Reports Regulatory Progress on Ceplene(TM) 5
(Date:11/21/2009)...1 Milvia Lopez, by her attorney MI...filed suit, in Supreme Court, New York County, bea...at while Ms. Lopez underwent a routine transesopha...ITAL , doctors used an HIV infected scope exposing...veral hours after being discharged from the proced...
(Date:11/21/2009)... based medical credentialing software company Inte... a partnerhsip with Amerinet, Inc., the leading he... help to transform quality care within the healthc...ember 21, 2009 -- ISG Group, LLC, doing business a... with Amerinet Inc., a leading national healthcare...
(Date:11/21/2009)...w Haven Dental Group merges their practice with th... (PRWEB) November 21, 2009...ers Dr. David Gibson, Dr. Dean Cloutier, Dr. John ... their growing practice with that of esteemed coll...decided he wanted to retire from dentistry in orde...
(Date:11/20/2009).... 20 The American Acad...ealth care reform legislation released this week t...urance individual coverage mandate. The actuaries ...l minimize adverse selection stemming from more re... bill. ,, "The individual mandate language shou...
(Date:11/20/2009)... Nov. 20 Rates of infect...ed in late October, but the pandemic flu virus con...age groups, including the elderly, according to a ...: DGX ), the world,s leading provider of diagnos...ts most recent Quest Diagnostics Health Trends(TM)...
Breaking Medicine News(10 mins):Health News:Patient Files Suit Against St. Vincent's Hospital in New York City as a Result of the Alleged Use by the Hospital of an HIV Infected Device During a Routine Procedure 2Health News:IntelliSoft Group and Amerinet Inc. Form Partnership to Transform Healthcare Delivery of Quality Patient Safety and Care 2Health News:New Haven Dental Group Expands Their Vision 2Health News:Actuaries to Senate: Strengthen Individual Mandate 2Health News:H1N1 Pandemic May Have Peaked in October in U.S., According to Quest Diagnostics 2Health News:H1N1 Pandemic May Have Peaked in October in U.S., According to Quest Diagnostics 3
...Roche announced today that a total of,20 U.S. and ...eloda(R),(capecitabine) have been accepted for pre...mposium (SABCS) in San AntonioDecember 12-14, incl...cts to be presented at the meeting compare the imp...
... 9 , The following is being issued by Norma... Recently there has been a frenzy of articles in...elivery system. We are told there are 46 million,p...care,rescue plan passed within ninety days of Pres...
... Voonami, Inc., a leading provider of outsourc...nounced today the opening of their first of severa...r in Orem, UT. Voonami also announced two new ada...ty of 300 watts per square foot. , ...
... Despite the recent economic downturn, natural...e industry are still experiencing a wellness boom,...rowth. Natural Healers, the Internet,s top natural... centers to help prospective students interested i...
... Full Spectrum - a leading FDA software develo...h the latest information on code obfuscation techn...able now. , (PRWEB) Decem... the impact of using a basic software engineering ...
...Therapeutics, Inc.,(Nasdaq and MTA: CTIC) announce...ter studies utilizing Zevalin(R) ([90Y]-ibritumoma... of Hematology (ASH) 50th Annual Meeting in,San Fr...initial treatment in,15 patients with advanced sta...
Other Medicine News:Health News:Twenty New Abstracts on Oral Xeloda(R) (capecitabine) Featured at the 31st San Antonio Breast Cancer Symposium 2Health News:Twenty New Abstracts on Oral Xeloda(R) (capecitabine) Featured at the 31st San Antonio Breast Cancer Symposium 3Health News:Average Americans Without Health Insurance Are Young and Healthy With Above Average Incomes 2Health News:Voonami, Inc. Announces Three New Adaptive Data Centers 2Health News:Natural Healers Researches Natural Health Careers to Make the Prospective Holistic Health Students' Job Easier 2Health News:Natural Healers Researches Natural Health Careers to Make the Prospective Holistic Health Students' Job Easier 3Health News:Aimed at Medical Device Makers, FDA Software Development Company Full Spectrum Releases Free Technical Report on Software Protection Technology 2Health News:Three Italian Multicenter Studies Report High (>70%) Rates of Complete Remission (CR) Utilizing Zevalin Radio-Immunotherapy (RIT) in Treatment of Newly Diagnosed or Relapsed or Refractory Non-Hodgkin's Lymphoma 2Health News:Three Italian Multicenter Studies Report High (>70%) Rates of Complete Remission (CR) Utilizing Zevalin Radio-Immunotherapy (RIT) in Treatment of Newly Diagnosed or Relapsed or Refractory Non-Hodgkin's Lymphoma 3Health News:Three Italian Multicenter Studies Report High (>70%) Rates of Complete Remission (CR) Utilizing Zevalin Radio-Immunotherapy (RIT) in Treatment of Newly Diagnosed or Relapsed or Refractory Non-Hodgkin's Lymphoma 4Health News:Three Italian Multicenter Studies Report High (>70%) Rates of Complete Remission (CR) Utilizing Zevalin Radio-Immunotherapy (RIT) in Treatment of Newly Diagnosed or Relapsed or Refractory Non-Hodgkin's Lymphoma 5
Symbia T, TruePoint SPECTCT system
Symbia T6, True Point SPECT·CT system
RADIANCE
QUALICHECK+
Medicine Products: